Results 161 to 170 of about 20,710 (242)

Estimating the Benefits of the Comprehensive Disease-modifying Pharmacological Treatment in Patients with Heart Failure. [PDF]

Card Fail Rev
Escobar C, Caravaca-Pérez P, Fernandez-Rodriguez JM, Gomez-Otero I, Lozano-Bahamonde A, Pérez-Cabeza AI, Pérez-Silvestre J, Rafols C, Saldaña-García J, Esteban-Fernández A.   +9 more
europepmc   +1 more source

Sex differences in leptin levels but not in the leptin response to sacubitril/valsartan in patients with heart failure with reduced ejection fraction. [PDF]

Front Cardiovasc Med
Shomanova Z, Ohnewein B, Semo D, Paar V, Fröhling T, Sindermann JR, Hoppe UC, Lichtenauer M, Zechowicz M, Motloch LJ, Pistulli R.   +10 more
europepmc   +1 more source

Clinical outcomes of heart failure with improved ejection fraction in patients treated with angiotensin receptor-neprilysin inhibitor. [PDF]

Korean J Intern Med
Kim DE, Kong MG, Kim S, Moon I, Park HW, Choi HO, Seo HS, Cho YH, Lee NH, Lee KY, Jang HJ, Kim JS, Choi IJ, Suh J.   +13 more
europepmc   +1 more source

Shock Timing in STEMI-CS: Management and Outcomes in a Resource-Limited Setting. [PDF]

JACC Adv
Remedios Carbonell LE, Perez Reyes M, Arteaga Guerra D, Prieto Guerra M, Martinez Garcia G, Santos Medina M, Almaguer Gongora L, Reyes B, Rodriguez Ramos M.   +8 more
europepmc   +1 more source

Circulating neprilysin hypothesis

Circulating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤
Lupón, Josep||, Santiago Vacas, Evelyn||, Cediel, Germán||, Codina, Pau||, Domingo, Mar||, Revuelta-López, Elena||, Zamora, Elisabet||, Spitaleri, Giosafat||, Santesmases, Javier||, Núñez, Julio||, Bayés-Genís, Antoni||   +10 more
openaire   +1 more source

Cost-Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors by Ejection Fraction and Drug Pricing in the United States: A Systematic Review. [PDF]

Circ Popul Health Outcomes
Alfie TJ, Wasfy JH, Kazi DS, Januzzi JL, Bellows BK, Cohen LP.   +5 more
europepmc   +1 more source

Soluble neprilysin and the translational continuum in cardio-oncology. [PDF]

Cardiooncology
Camilli M, Abbate A.
europepmc   +1 more source

Combating ageing beyond the cell: Emerging roles of extracellular proteostasis. [PDF]

FEBS J
Venkatesh SR, Gallotta I, Olabiyi BF, Choi YH, Inglesfield S, Kumita JR, Ewald CY, David DC.   +7 more
europepmc   +1 more source

Efficient brain delivery and sustained retention of antibodies via dual targeting of blood-brain barrier and intra-brain proteins. [PDF]

MAbs
Noguchi Y, Hironiwa N, Sato K, Yamazaki M, Kawashima M, Nagaya N, Nakagawa K, Okuda M, Kato A, Shu F, Haraya K, Kuramochi T.   +11 more
europepmc   +1 more source

Effect of Post-Ablational Angiotensin Receptor-Neprilysin Inhibitor on Atrial Fibrillation Recurrence: A Systematic Review and Meta-Analysis in Asian Population. [PDF]

Clin Cardiol
Wang Y, Zhang W, Shao Y, Dong Q, Gu Y, Wang H.   +5 more
europepmc   +1 more source